Qualcomm Stock Surges Despite Weak Guidance After Q2 2026 Earnings Beat 
Ford Q1 Earnings Beat Expectations, Stock Surges on Strong Guidance 
Nippon Express Stock Jumps as Elliott Investment Signals Strong Foreign Interest in Japan Logistics Sector 
T-Mobile Beats Q1 Earnings Expectations on Strong Postpaid Growth 
Starbucks Raises 2026 Outlook as Turnaround Strategy Boosts Sales and Earnings 
Meta Raises 2026 Capex Outlook Amid AI Spending Surge, Shares Drop After Earnings 
Micro Systemation Reports Q1 Loss Amid Strategic Investments and Revenue Growth 
Amazon Stock Dips Despite Record Earnings as AI Infrastructure Spending Surges 
Standard Chartered Q1 Profit Hits Record on Wealth and Investment Banking Growth 
DeepSeek Slashes AI Model Pricing to Boost Adoption and Challenge Global Rivals 
Seagate Stock Surges After Strong Q3 Earnings Beat and Bullish Outlook 
Alphabet Earnings Surge on AI Growth, Cloud Revenue, and Strong Search Performance 
Pershing Square Raises $5 Billion in Landmark U.S. IPO and Share Placement 
Why Paycom Was Named a 2026 Platinum Employer on the Where You Work Matters List 
AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales 
Samsung Reports Record Profit as AI Boom Drives Memory Chip Demand 
DUBLIN, Ireland, April 26, 2017 -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapies, today announced that members of its senior management team will present and participate in the Deutsche Bank 42nd Annual Health Care Conference on May 3rd at 8:40 AM ET in Boston, MA.
A live webcast of the company presentation can be accessed through the investor relations section of the Company’s website at www.prothena.com. Following the live presentation, a replay of the webcast will be available on the Company’s website for at least 90 days following the presentation date.
About Prothena
Prothena Corporation plc is a global, late-stage clinical biotechnology company establishing fully-integrated research, development and commercial capabilities. Fueled by its deep scientific understanding built over decades of research in protein misfolding and cell adhesion — the root causes of many serious or currently untreatable amyloid and inflammatory diseases — Prothena seeks to fundamentally change the course of progressive diseases associated with this biology. The Company’s pipeline of antibody therapeutic candidates targets a number of indications including AL amyloidosis (NEOD001), Parkinson’s disease and other related synucleinopathies (PRX002/RG7935), inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003), and ATTR amyloidosis (PRX004). The Company continues discovery of additional novel therapeutic candidates where its deep scientific understanding of disease pathology can be leveraged. For more information, please visit the Company’s website at www.prothena.com.
Contacts Investors: Tran Nguyen, CFO 650-837-8535, [email protected] Media: Ellen Rose, Head of Communications 650-922-2405, [email protected]
